NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Intellia Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$11.58+0.16 (+1.40%)
Close on Oct 19, 2026
- Market cap
- $1.55B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
–
Operating margin
-651.7%−416.2 pts over 5 years
Net margin
-609.9%−378.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +16.9% | +9.1% | +3.1% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -33.5% | -33.7% | -53.5% | |
| Return on assets | -16.6% | -26.6% | -40.6% | |
| Current ratio | 9.15 | 9.59 | 5.08 | |
| Capex to revenue | 37.4% | 6.2% | 1.7% | |
| Diluted shares | 22M | 56M | 108M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Intellia Therapeutics generated $1.70B from operations and spent $47.21M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.70B
Used
$47.21M
Capital expenditure$47.21M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-609.9%
×Asset turnover0.07×
×Equity multiplier1.32×
=Return on equity, FY2025-53.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -609.9% | 0.07× | 1.32× | -53.5% |
| FY2024 | -896.8% | 0.05× | 1.30× | -54.0% |
| FY2023 | -1326.5% | 0.03× | 1.23× | -42.1% |
| FY2022 | -909.8% | 0.04× | 1.24× | -41.7% |
| FY2021 | -810.5% | 0.03× | 1.26× | -34.2% |
| FY2020 | -231.5% | 0.11× | 1.27× | -33.7% |
| FY2019 | -1100.1% | 0.13× | 1.24× | -173.1% |
| FY2018 | -280.4% | 0.08× | 1.25× | -29.5% |
| FY2017 | -258.6% | 0.08× | 1.32× | -26.5% |
| FY2016 | -192.0% | 0.09× | 2.02× | -33.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$412.69M
- Cash generatingOperating cash flow above zero-$394.74M
- Return on assets improvedROA up on the prior year-39.9% → -34.7%
- Earnings backed by cashOperating cash flow above net income-$394.74M vs -$412.69M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.77 → 5.08
- No dilutionShare count did not rise99M → 108M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.04 → 0.06